Abstract
Positron emission tomography (PET) imaging of Alzheimers Disease (AD) offers the potential to provide early onset diagnosis and subsequent intervention, including guided treatment regimens. One of the restricting factors in clinical application of PET technology is the limited availability of radioligands with affinity to specific targets of interest. Given the short half-life of the most popular positron emitter currently used (18F; ∼120 min.) extremely rapid and efficient radiochemistry methods are needed to ensure required compounds are prepared and purified for administration within the 2-3 half life practical limit. Recent efforts to combine microwave mediated synthesis with advanced catalysis in the synthesis of specific categories of AD imaging agents will be presented.
Keywords: F18, PET, imaging agents, microwave, synthesis, radiochemistry
Current Alzheimer Research
Title: Microwave Accelerated Synthesis of PET Image Contrast Agents for AD Research
Volume: 7 Issue: 3
Author(s): A.E. Kallmerten and G.B. Jones
Affiliation:
Keywords: F18, PET, imaging agents, microwave, synthesis, radiochemistry
Abstract: Positron emission tomography (PET) imaging of Alzheimers Disease (AD) offers the potential to provide early onset diagnosis and subsequent intervention, including guided treatment regimens. One of the restricting factors in clinical application of PET technology is the limited availability of radioligands with affinity to specific targets of interest. Given the short half-life of the most popular positron emitter currently used (18F; ∼120 min.) extremely rapid and efficient radiochemistry methods are needed to ensure required compounds are prepared and purified for administration within the 2-3 half life practical limit. Recent efforts to combine microwave mediated synthesis with advanced catalysis in the synthesis of specific categories of AD imaging agents will be presented.
Export Options
About this article
Cite this article as:
Kallmerten A.E. and Jones G.B., Microwave Accelerated Synthesis of PET Image Contrast Agents for AD Research, Current Alzheimer Research 2010; 7 (3) . https://dx.doi.org/10.2174/156720510791050830
DOI https://dx.doi.org/10.2174/156720510791050830 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Kynurenine Pathway in Schizophrenia: Pathophysiological and Therapeutic Aspects
Current Pharmaceutical Design Ranolazine and its Antiarrhythmic Actions
Cardiovascular & Hematological Agents in Medicinal Chemistry A Series of New Hydrazone Derivatives: Synthesis, Molecular Docking and Anticholinesterase Activity Studies
Mini-Reviews in Medicinal Chemistry Recent Progress in Phosphoinositide 3-Kinases: Oncogenic Properties and Prognostic and Therapeutic Implications
Current Protein & Peptide Science Heterocyclic Secretase Inhibitors for the Treatment of Alzheimer’s Disease: An Overview
Central Nervous System Agents in Medicinal Chemistry WISP1 Neuroprotection Requires FoxO3a Post-Translational Modulation with Autoregulatory Control of SIRT1
Current Neurovascular Research Prognosis and Treatment of Ventricular Arrhythmias Following Myocardial Infarction
Current Cardiology Reviews Comparative Effectiveness of Agmatine and Choline Treatment in Rats with Cognitive Impairment Induced by AlCl<sub>3</sub> and Forced Swim Stress
Current Clinical Pharmacology Transitional Polytherapy: Tricks of the Trade for Monotherapy to Monotherapy AED Conversions
Current Neuropharmacology PPARs as Drug Targets to Modulate Inflammatory Responses?
Current Drug Targets - Inflammation & Allergy Anti-oxidative and Anti-microbial Activities of Purified MPN-1-1 from Persicaria nepalensis (Meisn.) Miyabe
Current Pharmaceutical Biotechnology Dexmedetomidine Use in General Anaesthesia
Current Drug Targets Precipitation Processes with Supercritical Fluids: Patents Review
Recent Patents on Engineering Targeting FGFR with BGJ398 in Breast Cancer: Effect on Tumor Growth and Metastasis
Current Cancer Drug Targets Isolation of a New Trypsin Inhibitor from the Faba Bean (Vicia faba cv. Giza 843) with Potential Medicinal Applications
Protein & Peptide Letters The Forward Path for Biopharmaceuticals and Biosimilars: Emerging Options in the Selection of Host Cell Systems
Current Biotechnology Editorial: (Thematic Issue: Off-label Treatments for Mental Health: Inappropriate or Unavoidable? A Special Issue to Help Get Through the Maze)
Current Pharmaceutical Design Editorial (Thematic Issue: Understanding the Role of Heteroreceptor Complexes in the Central Nervous System)
Current Protein & Peptide Science Naringenin Scaffold as a Template for Drug Designing
Current Traditional Medicine Pharmacological Modulation of Nitric Oxide Release: New Pharmacological Perspectives, Potential Benefits and Risks
Current Medicinal Chemistry